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Abstract 
Background: Cancers of the nasopharynx, nasal cavity, and accessory sinuses (“sinonasal”) are rare in England, with around 750 patients 
diagnosed annually. There are no specific National Institute for Health and Care Excellence (NICE) referral guidelines for these cancers and no 
primary care research published.
Objective: To identify and quantify clinical features of sinonasal cancer in UK primary care patients.
Methods: This matched case–control study used UK Clinical Practice Research Datalink (CPRD) data. Patients were aged ≥40 years with a diag-
nosis of sinonasal cancer between January 1, 2000 and December 31, 2009 and had consulted their GP in the year before diagnosis. Clinical 
features of sinonasal cancer were analysed using conditional logistic regression. Positive predictive values (PPVs) for single and combined fea-
tures were calculated.
Results: In total, 155 cases and 697 controls were studied. Nine symptoms and one abnormal investigation were significantly associated with 
the cancer: nasal mass; odds ratio, 95 (95% confidence interval 7.0, 1315, P = 0.001); head and neck lumps, 68 (12, 387, P < 0.001); epistaxis, 
17 (3.9, 70, P < 0.001); rhinorrhoea, 14 (4.6, 44, P < 0.001); visual disturbance, 12 (2.2, 67, P = 0.004); sinusitis, 7.3 (2.2, 25, P = 0.001); sore 
throat, 6.0 (2.0, 18, P = 0.001); otalgia, 5.4 (1.6, 18, P = 0.007); headache, 3.6 (1.4, 9.5, P = 0.01); raised white cell count, 8.5 (2.8, 27, P < 0.001). 
Combined PPVs for epistaxis/rhinorrhoea, epistaxis/sinusitis, and rhinorrhoea/sinusitis were 0.62%.
Conclusion: This is the first primary care study identifying epistaxis, sinusitis, and rhinorrhoea as part of the clinical prodrome of sinonasal 
cancer. Although no PPVs meet the 3% NICE referral threshold, these results may help clinicians identify who warrants safety-netting and pos-
sible specialist referral, potentially reducing the number of advanced-stage diagnoses of sinonasal cancer.
Lay Summary 
Sinonasal cancer occurs in the back of the nose or in the sinuses. It is rare in the United Kingdom, with most cases being diagnosed at an 
advanced stage. Delayed presentation and non-specific symptoms often lead to diagnosis at a later stage, with consequently poorer survival 
outcomes. Currently, there is no research describing the symptoms presented by these patients to their general practitioner (GP), nor referral 
guidelines for primary healthcare professionals. The aim of this study was to detect the symptoms of patients aged ≥40 years, diagnosed with 
sinonasal cancer in primary care. Three symptoms in the year before their diagnosis were linked with sinonasal cancer: nosebleeds, runny nose, 
and sinusitis. These symptoms may help GPs to identify possible sinonasal cancer patients earlier, though each symptom was low-risk on its 
own.
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Background
Cancer of the nasopharynx, nasal cavity, and accessory 
sinuses are rare in the United Kingdom, accounting for <1% 
of all malignancies.1,2 In 2017, in England, 529 patients (60% 
male) were diagnosed with nasal cavity and accessory sinuses 
cancers: a further 218 patients (70% male) were diagnosed 
with nasopharyngeal cancer.2 The incidence of these cancers is 
less than 1 in 100,0003,4 and has remained static.4 The 5-year 
UK survival rate for both cancer sites is approximately 50%.5
Currently, there are no referral recommendations for 
these cancers within National Institute for Health and Care 
Excellence (NICE) guidelines.6 Referral guidelines for head 
and neck cancers only include specific recommendations for 
thyroid, larynx, and oral cancers. General practitioner (GP) 
referral is the commonest route to diagnosis (39%) for naso-
pharyngeal cancer, with those presenting as an emergency 
having the poorest survival outcomes.7 Previous secondary and 
tertiary care studies have reported multiple sinonasal disease 
symptoms including epistaxis,8 head and neck masses,9 nasal 
obstruction,10 rhinorrhoea,11 otalgia,12 headache,13 cranial 
nerve palsies, and visual disturbances.14 Unilateral sinonasal 
disease is more likely to be associated with malignancy than 
bilateral disease.15 Epistaxis and nasal obstruction are com-
monly reported16: in some cases, epistaxis predated diagnosis 
by 4 years.17 Symptoms of nasopharyngeal cancers include 
unilateral ear problems,12 cervical lymphadenopathy,9 and 
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Key messages
 • This is the first primary care study of the clinical prodrome of sinonasal cancer.
 • Rhinorrhoea, headache, and epistaxis were most commonly reported.
 • Nasal mass and head and neck lumps produced the highest positive predictive values (PPVs).
 • All PPVs are below the NICE referral threshold.
 • Patients who re-attend with these symptoms may warrant ENT referral.
 • Earlier recognition of this rare cancer might improve survival outcomes.
neck masses.13 This variation may be attributed to the dis-
parate anatomical location of these cancers, with symptoms 
reflecting affected structures. These studies have combined 
head and neck cancer sub-sites differently. For sinonasal 
cancers, the mean duration of reported symptoms was ap-
proximately 6 months, with most presenting with advanced 
disease.18
The posterior nasal cavity, past the turbinates, is not easily 
visualized.19 This may contribute to diagnostic delay if the 
physician is unsure whether referral is warranted.20 Anterior 
rhinoscopy may be performed in primary care, but definitive 
endoscopic examination is reserved for specialist settings.19
The clinical prodrome of cancers of the nasopharynx, 
nasal cavity, and accessory sinuses (hereafter referred to as 
“sinonasal” cancer) has yet to be elucidated. The aim of this 
study was to identify the clinical features of sinonasal cancers 
in UK primary care patients, quantifying their individual and 
combined risk.
Methods
This was a matched case–control study using primary care 
electronic patient records obtained from the UK’s Clinical 
Practice Research Datalink (CPRD). The CPRD collects an-
onymized patient records from 674 general practices.21 This 
database includes details of symptoms, investigations, diag-
noses, and patient demographics.
Cases and controls
A list of 20 nasopharyngeal and sinonasal cancer codes (ICD-
10 codes C11, C30, C31) were collated from the CPRD 
master code library to identify relevant patients (specific 
READ codes available from authors upon request). “Read 
codes” are alphanumerical codes assigned to clinical terms. 
They are used in UK healthcare settings to identify symptoms, 
investigations, and treatments. It is similar to an electronic 
thesaurus for clinical terminology and allows you to search 
for the same term across different computer systems. Three 
codes were subsequently excluded as they involved the bony 
structure, cartilage, or unspecified area of the nose. Cases 
aged ≥40 years, diagnosed with sinonasal cancer between 
2000 and 2009, were selected if they attended their GP in the 
year prior to diagnosis. Individuals aged 40+ were selected to 
reflect the age group where cancer incidence in the general 
population begins to rise. Each case was assigned up to five 
controls, matched via sex, age, and general practice. The date 
of diagnosis (“index date”) was determined by the first record 
of a sinonasal cancer code. Controls were matched to their 
respective case’s index date as per previous protocol.22 GP 
surgery was chosen as a proxy for socioeconomic status and 
to accommodate within-practice coding protocols. Exclusion 
criteria were: patients who had not consulted their GP in the 
year before the index date and cases without controls.
Selection of putative clinical variables
Diagnostic features (clinical symptoms and investigations) 
were identified through literature searches using PubMed, 
Google Scholar, and ScienceDirect. Search terms included 
“nasopharyngeal/sinonasal cancer symptoms,” “early signs/
indications/presentations of nasopharyngeal/sinonasal 
cancer,” and “primary care nasopharyngeal/sinonasal cancer.” 
Online forums were searched for any patient-reported symp-
toms of nasopharyngeal/sinonasal cancer prior to diagnosis. 
The CPRD master list contains over 100,000 medical codes 
mapped to READ codes. These correlate to individual clinical 
features and were assembled into feature-specific libraries, in 
line with our previous studies.23,24 Occurrence of these fea-
tures in the year before the index date was recorded. Features 
present in ≥2% of cases were retained. Following our previous 
protocol, fractures were identified in both cases and controls 
to test for recording bias.23,24 Tests were considered abnormal 
if reported values fell outside the laboratory’s normal range. 
Patients within the expected ranges were grouped with those 
who had no test results.
Composite variables
Thirteen composite symptom variables were generated: 
“hyposmia,” “catarrh,” “epiphora,” “facial pain,” “hearing 
loss,” “nasal mass,” “nasal septal ulcers,” “neck pain,” 
“ophthalmalgia,” “proptosis,” “rhinorrhoea,” “sinusitis,” and 
“tinnitus.” Hyposmia was comprised of agnosia, taste dis-
orders, and complete anosmia. Catarrh included laryngitis, 
pharyngitis, tonsillitis, and infection. Nasal mass referred to 
both cysts and polyps. Nasal septal ulcers included perfor-
ation and necrosis. Rhinorrhoea was composed of rhinitis, 
nasal obstruction, and nasal discharge. The remaining vari-
ables contained codes with alternately worded derivatives 
and/or specified anatomical locations. Tests were combined to 
create the following groups: “raised inflammatory markers” 
(inclusive of plasma viscosity, erythrocyte sedimentation rate, 
and C-reactive protein) and “liver function tests” (measuring 
hepatic enzymes AST or ALT and bilirubin).
Analysis and statistical methods
Conditional logistic regression was used for analysis. 
Individual features associated with sinonasal cancer with a 
P-value threshold of ≤0.1 in univariable analyses progressed 
to multivariable analysis. The final multivariable model used 
a P-value for retention of ≤0.01 and included clinically plaus-
ible interactions.
Positive predictive values (PPVs) for features of sinonasal 
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multiplied by the prior odds of a feature equating to the pos-
terior odds of having the cancer). The prior odds were deter-
mined by age-specific national incidence rates for sinonasal 
cancers in 2008. PPVs were only calculated for consulting 
patients aged 50+. PPVs were not calculated if <5 cases had 
the feature; when <10 cases or controls had the combined 
features, 95% CIs were omitted. PPVs for persistent symp-
toms were not calculated due to the limited number of cases. 
The posterior odds were subsequently divided by 0.9, based 
on 697 of a total 779 (89%) attending their GP in the pre-
vious year. The calculations in this study reflect the risk of an 
undiagnosed cancer based on symptom reporting by patients 
who physically present themselves to their GP. Thus 90% of 
the control population had the opportunity to report symp-
toms to their GP in person.
Power calculation
The CPRD provided 177 cases and 884 controls. In accord-
ance with our previous studies, power calculations were 
used in place of sample size calculations.24,25 The correl-
ation between cases and controls was zero as both were 
assumed to have the same level of exposure. Using a case–
control ratio of 1:5 with a 5% two-sided alpha produced 
>92% power to detect a change in common variables of 
20% in cases and 10% in controls. All analyses used Stata/
SE version 16.
Results
The CPRD supplied 1,061 patients (177 cases; 884 controls). 
Upon application of the exclusion criteria shown in Figure 1, 
a final number of 852 patients were included, (155 cases; 697 
controls).
Patient demographic and consultation information is given 
in Table 1. Cases consulted significantly more frequently than 
controls in the year before diagnosis (P < 0.0001; rank-sum 
exact test).
Clinical features
Thirty-two symptoms and fourteen investigations were con-
sidered initially; ten clinical features remained significant in 
the final model. The frequencies, univariable likelihood ratios, 
and multivariable odds ratios for these features are shown in 
Table 2. Sore throat and raised white cell counts were the only 
clinical features not previously reported in the secondary care 
literature but were present in our final model. From the 155 
cases, 95 (61%) had at least one of the final model features re-
corded in the year preceding their diagnosis. The proportion 
of patients with a fracture did not differ between cases and 
controls (P < 0.580).
Positive predictive values
Single and combined PPVs were calculated for patients aged 
≥50 years. The highest single PPV was 0.09% for head and 
neck lumps, well below the NICE referral threshold of 3%. 
The remaining PPVs were 0.06% for nasal polyps, 0.05% 
for visual disturbance, 0.04% for epistaxis, 0.03% for 
rhinorrhoea, 0.02% for otalgia, sinusitis, and headache, and 
0.01% for sore throat and raised white cell count. The risk 
increased when patients reported more than one symptom; 
despite this, the highest risk was 0.62% for the following 
symptom combinations: epistaxis with rhinorrhoea, epistaxis 
with sinusitis, and rhinorrhoea with sinusitis. However, 




This is the first study to identify and quantify the clinical fea-
tures of sinonasal cancer in primary care. Features found to 
be associated with sinonasal cancer were similar to those re-
ported in secondary care literature, with the exception of sore 
throat and a raised white cell count which are reported for 
the first time here. All single symptoms produced risk esti-
mates of below 0.1%, reflecting the rarity of this cancer. The 
highest risk estimates were 0.62% for three pairs of symp-
toms: “epistaxis and rhinorrhoea,” “epistaxis and sinusitis,” 
and “rhinorrhoea and sinusitis.” Whilst these figures do not 
meet the 3% NICE threshold for urgent referral, they have 
now been identified as relevant primary care symptoms of 
sinonasal cancer and may warrant including as specific guid-
ance in the next NICE cancer guideline update. With a lack 
of existing formal guidance, these results should assist GPs 
Fig. 1. Exclusion criteria of 177 UK CPRD patients diagnosed with 
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in their clinical decision making, particularly in patients with 
unresolved symptoms.
Strengths and limitations
This is the first primary care study to investigate the clinical 
prodrome of sinonasal, accessory sinus, and nasopharyngeal 
cancers. Whilst these represent three distinct cancer sites, they 
have been grouped together as they follow a referral pathway 
to the same specialist. The results are therefore relevant for 
patient selection to secondary care. The study used the CPRD, 
which is representative of the UK population—ensuring gen-
eralisability of results. The quality and validity of primary 
care data collated by the CPRD have been well documented.26 
This study was also adequately powered and the sample size 
was large, when compared to secondary care literature. The 
study period also involved direct transferral of laboratory 
results, reducing the likelihood of transcription errors. By 
reviewing current literature and patient forums, relevant fea-
tures are unlikely to have been omitted. In calculating PPVs 
on the consulting population only, the results are directly ap-
plicable to clinical practice.
This study is reliant on coded symptom recording. Multiple 
codes may pertain to each symptom but a dominant generic 
code is usually selected. For two symptoms, nasal obstruction 
and epistaxis, we were not able to determine whether they 
were unilateral or bilateral symptoms. Although this study’s 
sample size was large compared to most secondary care 
studies, some symptoms combinations were not estimable 
due to low numbers. Similarly, caution should be advised in 
interpreting the results due to the wide confidence intervals.
Patients with sinonasal cancer consulted their GP more 
often than controls thereby having more chances to report 
symptoms. Relevant symptom information may be recorded 
in a “free-text” section which is inaccessible to researchers. 
This could result in missing data or an underestimation of 
symptom frequency, though this appears to be relatively 
minor.27 Bias from differential recording of symptoms ap-
pears to be relative to the under-recording of low-risk symp-
toms (like those seen in this study) in controls.27 If this bias 
has been present, our risk estimates, both odds ratios and 
PPVs may be slight under-estimates. There was no linkage to 
cancer registry data, therefore the stage at diagnosis for these 
patients is unknown.
Comparison with existing literature
Sinonasal cancer patients consulted their GP on average 
twice as often as controls in the year preceding their diag-
nosis. This suggests that patients recognize a development 
of symptoms warranting medical appraisal—and provides 
the GP with opportunity to investigate. The features iden-
tified in this study mostly mirror those from secondary 
and tertiary care1,8,10–14,17,18,28–30; however, the frequency 
of symptom reporting varied. Epistaxis,10,13,28 headache,13 
otalgia,13 and rhinorrhoea10 were reported both in sec-
ondary care and in this study. Secondary care reports 
from the United Kingdom identified palpable neck lumps 
Table 1. Characteristics and consultation rates of 155 UK patients, diagnosed with sinonasal cancer (2000–2009) and 697 matched controls.
 Cases Controls
Male Female Total Male Female Total 
(n = 102) (n = 53) (n = 155) (n = 450) (n = 247) (n = 697)
Median (IQR) age in years at diagnosis 64 63 64 65 63 64
(55–72) (56–74) (55–73) (56–73) (55–74) (56–74)
Median (IQR) number of consultations in the 12-month preceding diagnosis 14 15 15a 7 8 7a
(9–22) (11–24) (10–23) (3–12) (4–15) (3–13)
aCases consulted significantly more frequently than controls in the year before diagnosis (P < 0.0001; rank-sum exact test).
Table 2. Clinical features of sinonasal cancer in the UK patients aged ≥40 years: cases (n = 155) and controls (n = 697).
 Cases, n (%) Controls, n (%) Univariate likelihood ratio (95% CI) Multivariate OR (95% CI) P-value 
Symptom
 Rhinorrhoea 28 (18) 11 (2) 12 (5.8–22) 14 (4.6–44) <0.001
 Headache 22 (14) 15 (2) 6.6 (3.5–12) 3.6 (1.4–9.5) 0.01
 Epistaxis 19 (12) 6 (0.9) 14 (5.8–35) 17 (4.0–70) <0.001
 Sinusitis 18 (12) 9 (1) 9.0 (4.1–20) 7.3 (2.2–25) 0.001
 Head and neck lumps 18 (12) 3 (0.4) 27 (8.1–90) 68 (12–388) <0.001
 Otalgia 13 (8) 8 (1) 7.3 (3.1–17) 5.3 (1.6–18) 0.007
 Sore throat 10 (6) 12 (2) 3.8 (1.7–8.5) 6.0 (2.0–18) 0.001
 Visual disturbances 9 (6) 2 (0.3) 20 (4.4–93) 12 (2.2–67) 0.004
 Nasal mass 7 (5) 1 (0.1) 31 (3.9–254) 95 (7–1315) 0.001
Investigations
 Raised white cell count 14 (9) 14 (9) 4.5 (2.2–9.2) 8.5 (2.7–27) <0.001
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as the most common symptom (55%), but most patients 
presented at advanced stages.28 Deafness/tinnitus was 
the second commonest feature,28 but this was not found 
in our primary care patient data. Similarly, cranial nerve 
palsies were only found in secondary care patients9; these 
differences may reflect the stage of cancer.30 Despite these 
findings, just under 40% of patients are not represented 
by these clinical features. It is likely that these patients 
reported features not common enough to be included, or 
those that failed to reach significance.
Implications for practice
Current NICE guidelines for possible head and neck cancer 
only provide referral recommendations for larynx, thyroid, 
and oral cancers. There has been no primary care evidence 
base for sinonasal cancer until now. Although neither the 
single nor the combined PPVs of our final model features meet 
the 3% NICE urgent referral threshold, clinicians now know 
how this rare cancer may present in primary care. GPs may 
want to consider referral if a patient re-attends with persistent 
symptoms reported here, particularly multiple ones. The re-
sults of this study warrant including as a separate sub-site 
of head and neck cancers in future updates of NICE cancer 
guidelines.
Conclusion
We have identified and quantified ten features associated 
with sinonasal cancer in primary care. Whilst the PPVs do 
not warrant immediate referral, patients with persistent fea-
tures ought to be considered for further investigation. Clinical 
acumen and experience, which is difficult to quantify, may 
remain the most important factor in identifying patients with 
potential sinonasal cancer.31
Supplementary material
Supplementary material is available at Family Practice online.
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